Sanofi India (formerly known as Aventis Pharma) has launch of AllStar, its first indigenously manufactured re-usable insulin pen. Developed especially for Indian patients by Sanofi’s Medical Device Development team at Frankfurt, AllStar, is indicated for use of insulinized patients using Sanofi’s insulin portfolio. The AllStar re-usable insulin pen conforms to ISO (International Organization for Standardization) standards and is equipped with state-of-the-art, unparalleled 10-in-1 features.
AllStar is custom-made for patients in India. It helps improve both insulin initiation and compliance and brings ease and reassurance to the lives of Indian patients, giving them the convenience of international standards at an affordable price. Further, the launch of AllStar is a significant milestone in Sanofi India’s diabetes growth story, and also underlines the Sanofi Group’s focus on diabetes, emerging markets and its regionalized approach to finding solutions that are adapted to local needs.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |